"We are also pleased to see restored growth in Dosimetry as well as that Services now represent a third of proton therapy revenues, and confirming it as an important recurring revenue driver.
"We expect the momentum across the business to continue in the second half, especially in the proton therapy market, leading us to be confident in increasing our 2015 guidance to 15-20% top line growth from the 10% average previously stated and we confirm a trend towards 30% dividend payout."
Ad Statistics
Times Displayed: 22687
Times Visited: 478 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Conference Call Information:
IBA will host a conference call and webcast today at 2pm CEST / 1pm BST / 8am EDT. Olivier Legrain, Chief Executive Officer, and Jean-Marc Bothy, Chief Financial Officer, will host the call which will be conducted in English. The conference call will be webcast live and can be accessed on the investor page of the IBA website at: www.iba-worldwide.com/?page=investor-relations. If you would like to participate in the Q&A, please dial (PIN code 21347202#):
Belgium: +32 2 404 03 05
UK: +44 207 750 9926
NL: +31 207 133 488
LU: +352 278 601 66
US: +1 914 885 0779
FR: +33 172 040 033
The webcast presentation will be available on the Company's website shortly after the call.
Financial calendar
Third Quarter business update November 17, 2015
Full Year results 2015 March 24, 2016
Read the full Half Year 2015 press release
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1 100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com
*
Proteus®ONE is the brand name of a new configuration of the Proteus® 235.
For further information please contact:
IBA
Jean-Marc Bothy
Chief Financial Officer
Tel: +32 10 47 58 90
Thomas Ralet
Vice-President Corporate Communication
+32 10 47 58 90
communication@iba-group.com
